At the forefront of tonic signaling is leptin, a peptide hormone secreted primarily by adipose tissue. It acts as a steady, baseline indicator of the body’s energy stores, directly informing the brain about overall energy balance. Through its interaction with areas such as the arcuate nucleus, leptin influences appetite suppression and energy utilization, thereby maintaining homeostasis over chronic periods. In contrast, peptides like ghrelin, cholecystokinin (CCK), gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY) execute their effects episodically, rapidly modulating feeding behaviors and digestive processes in response to specific meals.

Among these, ghrelin stands out for its unique biochemistry and function. Synthesized predominantly in the stomach, ghrelin is a 28-amino acid peptide, distinguished by an O-acyl modification at its serine residue, a feature critical for its biological activity. This post-translational acylation, catalyzed by ghrelin O-acyltransferase, enables the peptide to bind its receptor, triggering appetite-stimulating effects. Importantly, ghrelin circulates in two main forms: acylated ghrelin (AG), which is bioactive, and unacylated ghrelin (UAG), which lacks similar receptor affinity and exhibits divergent effects. Consequently, accurate measurement of AG in research requires meticulous sample handling to preserve the labile octanoyl group, a moiety prone to rapid degradation by proteases both in vivo and ex vivo.

The challenge posed by ghrelin’s instability has spurred comprehensive investigations into optimal blood sampling and processing techniques. Studies underscore the necessity of immediate cooling of blood samples, pre-chilling collection tubes, and rapid refrigerated centrifugation to prevent deacylation. Additionally, incorporation of protease inhibitors directly into collection tubes ensures immediate neutralization of degrading enzymes, safeguarding peptide integrity. For certain assays, acidification of samples with hydrochloric acid further stabilizes acylated ghrelin during long-term storage and repeated freeze-thaw cycles, highlighting the intricate balance required between biological nuance and laboratory precision.

Parallel to ghrelin, incretin hormones GIP and GLP-1 command vital roles in nutrient-induced insulin secretion and appetite regulation. GIP, secreted primarily by the small intestine, exists predominantly as the intact 42-amino acid peptide (GIP1-42), rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) into its inactive form GIP3-42. This rapid enzymatic conversion results in a circulating pool where the metabolite predominates, posing analytical challenges. Current consensus recommends measurement of “total GIP” to approximate secretory responses, while selectively analyzing the intact form may be necessary when endocrine-specific dynamics are under scrutiny.

GLP-1 shares a similar dual existence, secreted in two intact isoforms: GLP-1(7-37) with a glycine extension and amidated GLP-1(7-36) amide, with the latter predominating in human circulation. Its fleeting half-life, estimated at 1 to 2 minutes due to swift DPP-4 degradation into GLP-1(9-37) and GLP-1(9-36) amide metabolites, complicates peripheral measurement. Remarkably, only a small fraction of secreted GLP-1 reaches the venous circulation intact, with its primary satiety effects mediated via vagal nerve afferents before rapid degradation ensues. Despite early beliefs regarding the inactivity of its degraded metabolites, emerging evidence suggests these fragments may possess biological significance, opening new avenues for metabolic research.

Methodological rigor remains paramount when quantifying GIP and GLP-1. To prevent ex vivo peptide degradation during blood sampling, addition of DPP-4 inhibitors into collection tubes is standard. Techniques such as ethanol precipitation or solid-phase extraction further refine sample purity by reducing interference from plasma proteins, yielding more reproducible measures of active hormone concentrations. Intriguingly, while protease inhibitors like aprotinin were conventionally used to maintain peptide stability, recent evidence indicates that EDTA-coated tubes—even lacking these inhibitors—may suffice in tightly controlled clinical trial settings, provided that samples are processed promptly.

Assay variability poses another layer of complexity. Comparative assessments between commercially available enzyme-linked immunosorbent assays (ELISAs) and traditional radioimmunoassays (RIAs) reveal substantial discrepancies in sensitivity and specificity across different platforms and even batches. Therefore, researchers must carefully select assays with high fidelity tailored to the isoforms of interest and maintain analytical consistency within studies. The recent identification of a shorter GIP peptide variant (GIP1-30 amide) with potential biological activity—but not detected by most assays—further underscores the evolving landscape and the need for assay development that captures the full peptide spectrum.

Peptide YY (PYY), secreted chiefly from distal intestinal L-cells, exists mainly as full-length PYY1-36 and truncated PYY3-36, the latter generated through DPP-4-mediated cleavage. This truncation is critical; only PYY3-36 exerts potent appetite-suppressing effects by selectively activating the neuropeptide Y (NPY) Y2 receptor within the hypothalamus. Consequently, sample handling methodologies must prevent ex vivo conversion and proteolytic degradation beyond PYY3-36, ensuring accurate representation of biologically active forms.

Manufacturers often recommend the proactive addition of DPP-4 inhibitors and broad-spectrum protease inhibitors like aprotinin during blood collection to preserve PYY integrity. In practice, blood may be drawn into syringes containing DPP-4 inhibitors followed by aprotinin treatment, thereby arresting post-collection enzymatic activity. However, some studies suggest that the rapidity of sample processing itself may mitigate peptide breakdown, casting doubt on the universal necessity of such inhibitors in every context. Notably, EDTA combined with aprotinin treatment effectively prevents degradation of PYY3-36 into inactive PYY3-34 fragments, emphasizing tailored approaches based on research objectives.

Where direct quantification of PYY3-36 is unattainable, total PYY measurements serve as a pragmatic proxy due to generally parallel secretion patterns of PYY1-36 and PYY3-36 across feeding states. Nonetheless, situations exist where the ratio between these forms shifts, potentially distorting interpretations if isoform-specific analysis is neglected. Hence, prioritization of PYY3-36 assays is crucial in investigations aiming to dissect the precise appetite-modulating contributions of this peptide.

Collectively, these insights affirm that the measurement of appetite-related peptides, though laden with methodological intricacies, is indispensable for unraveling the neuroendocrine regulation of feeding and metabolism. Precision in sample handling, inhibitor selection, assay choice, and timing is vital to accurately capture the dynamic milieu of these hormones, thereby enhancing reproducibility and interpretability across studies. This knowledge is foundational not only for basic physiological inquiry but also for the development of therapeutic strategies targeting obesity, diabetes, and related metabolic disorders.

Moreover, the complexity inherent to peptide isoforms, rapid enzymatic degradation, and tissue-specific secretion profiles reflects the exquisite biological tuning that underpins appetite regulation. Future research harnessing advances in analytical chemistry and molecular biology promises to refine measurement techniques further, elucidating nuanced pathways and opening avenues for personalized interventions. As such, appetite-related peptides represent a captivating frontier in metabolic science, bridging molecular detail with systemic health implications.

Understanding these neurohumoral messengers thus transcends mere academic interest, holding transformative potential for nutritional science, clinical diagnostics, and pharmacological innovation. The evolving toolkit for their assessment exemplifies the synergy of technological prowess and biological insight, charting new terrain in the quest to decode the molecular language of hunger and satiety.

Subject of Research:
Appetite-related peptides and their neurohumoral role in regulating food intake and energy expenditure, with methodological considerations for their measurement.

Article Title:
The mixed-meal tolerance test as an appetite assay: methodological and practical considerations

Article References:
King, J.A., Thackray, A.E., Gibbons, C. et al. The mixed-meal tolerance test as an appetite assay: methodological and practical considerations. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01866-7

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41366-025-01866-7

Keywords:
Appetite peptides, ghrelin, leptin, GIP, GLP-1, PYY, energy balance, neurohumoral control, metabolic regulation, hormone assay methodologies, peptide stability, protease inhibitors

Tirzepatide and semaglutide belong to a class of compounds that engage the GLP-1 receptor, with tirzepatide functioning as a dual agonist targeting both GLP-1 and GIP receptors. These agents have revolutionized the pharmacological management of obesity by significantly reducing appetite and improving glucose homeostasis, yet their influence on energy expenditure—the amount of energy the body burns over time—was less clearly understood prior to this investigation. Clarifying these effects is critical, as sustainable weight loss depends not only on caloric intake reduction but also on maintaining or enhancing metabolic rate to prevent weight regain.

In this state-of-the-art study, a cohort of 24 mice was subjected to a prolonged high-fat diet designed to induce obesity before dividing them into three groups for intervention: a control group receiving no pharmacological treatment, a semaglutide-treated group, and a tirzepatide-treated group. Both drug-treated groups received daily dosages of 10 nmol/kg for four consecutive weeks, followed by a washout period of two weeks wherein treatment was halted but the high-fat diet was maintained. This experimental design enabled researchers to observe both the acute drug effects and any lasting metabolic adaptations that persisted after cessation.

One of the critical innovations of this work was the use of indirect calorimetry to continuously monitor energy expenditure in real-time. This technique, which quantifies oxygen consumption and carbon dioxide production, allows precise estimation of whole-body energy utilization. Conducting the experiments at thermoneutrality further controlled environmental variables, eliminating the confounding effects of cold-induced thermogenesis, thus ensuring that changes in metabolic rate were drug-related rather than a response to ambient temperature stress.

Remarkably, mice treated with tirzepatide displayed a substantial increase in energy expenditure as early as four days into the regimen. This elevated metabolic rate was sustained through the second week of treatment before gradually declining to baseline levels. Intriguingly, these changes were not linked to increased locomotor activity, suggesting a direct pharmacological effect on metabolic tissues rather than behavioral changes. On the other hand, semaglutide treatment resulted in a pronounced initial decrease in energy expenditure during the first three days, reflecting a transient metabolic slowdown during weight loss.

Body weight changes mirrored these metabolic shifts. Control animals experienced modest weight gain over the treatment period, averaging a 2.7-gram increase. In stark contrast, tirzepatide-treated mice lost an average of 15.6 grams, while semaglutide-treated mice shed approximately 8.3 grams. Most of this weight loss occurred in the first week, coinciding with profound reductions in food intake. These data highlight tirzepatide’s superior efficacy in promoting rapid and significant weight loss, potentially attributable to its unique ability to elevate energy expenditure transiently.

The respiratory exchange ratio (RER), a parameter indicating substrate utilization, further illuminated how these drugs shift metabolic fuel preference. Both semaglutide and tirzepatide initially lowered the RER, suggesting enhanced fat oxidation and reduced reliance on carbohydrate metabolism. This metabolic adaptation supports weight loss by mobilizing fat stores to meet energy demands. However, after three weeks of continuous dosing, RER values returned to baseline, and during the washout period, they increased above control levels as animals resumed higher caloric intake, indicating a reversible effect linked to drug presence.

Dr. Simone Bossi, co-leading the study at Gubra’s Pharmacology Research department in Denmark, explained the clinical relevance: “Our findings elucidate how these drugs not only suppress appetite but exert distinct effects on energy expenditure, which are crucial for sustained weight loss. Semaglutide’s initial decrease in metabolic rate aligns with classic physiological energy conservation during calorie restriction, while tirzepatide’s transient metabolic boost may offer an advantage for weight reduction.” These mechanistic insights help explain tirzepatide’s more potent anti-obesity effects observed in clinical settings.

Critically, the cessation of treatment reversed the metabolic adaptations. During the two-week washout period, energy expenditure returned to control levels for both drug groups, and the mice increased their food consumption, ultimately nullifying prior metabolic gains. This phenomenon underscores a key challenge in obesity pharmacotherapy: maintaining long-term weight loss requires not only suppressing intake but also sustaining or enhancing energy expenditure to offset adaptive responses that favor weight regain.

These revelations pave the way for a paradigm shift in the development of obesity treatments. Current therapies primarily focus on appetite suppression, yet the transient metabolic effects suggest that augmenting energy expenditure pharmacologically could potentiate and prolong weight loss outcomes. Future investigations aimed at dissecting the molecular pathways mediating tirzepatide’s metabolic activation may uncover new targets for drug development with an emphasis on enduring metabolic elevation, thereby overcoming the body’s compensatory mechanisms.

Moreover, this research highlights the importance of timing and dosage strategies in anti-obesity drug administration. Understanding the temporal metabolic fluctuations induced by these drugs can inform treatment regimens that optimize efficacy while minimizing metabolic adaptation. Integrating metabolic monitoring tools such as indirect calorimetry in clinical settings could further personalize therapy by identifying responders and tailoring dosing schedules to individual metabolic profiles.

In summary, this pioneering study elucidates critical differences in how tirzepatide and semaglutide modulate metabolism beyond appetite suppression. Tirzepatide’s unique ability to transiently elevate energy expenditure, coupled with both drugs’ promotion of fat oxidation, contributes to robust weight loss, but these metabolic changes dissipate rapidly after treatment withdrawal. These findings underscore the dynamic interplay between pharmacology and physiology in obesity management and open exciting avenues for novel therapeutic strategies targeting sustained energy expenditure enhancement.

As obesity continues to be a global health crisis demanding effective long-term interventions, understanding and manipulating metabolic adaptations to therapy represent a promising frontier. The nuanced insights from this study not only advance scientific knowledge but also provide practical implications for improving patient outcomes. Ongoing research will undoubtedly expand on these findings to develop drugs that harness and maintain beneficial metabolic shifts, ultimately transforming the landscape of obesity treatment and chronic weight management.

Subject of Research: Metabolic adaptations and energy expenditure effects of tirzepatide and semaglutide in obesity treatment.

Article Title: Distinct Metabolic Effects of Tirzepatide and Semaglutide Uncovered in Preclinical Obesity Model.

News Publication Date: 13-May-2025

Keywords: tirzepatide, semaglutide, energy expenditure, obesity, metabolic adaptation, GLP-1 receptor agonists, weight loss, fat oxidation, indirect calorimetry, pharmacology, weight maintenance